Skip to main content

Новости и события

Educational Webinar Library

The clinical value PET myocardial blood flow quantification and practical aspects of implementing a PET Cardiac Program

The clinical value of myocardial flow quantification is supported by numerous observational and clinical studies in various populations. Its use is no longer restricted to a few academic centers as the technology advances and guidelines evolves. In this webinar two leading figures in the field discussed the clinical value and practical aspects of PET quantification in cardiovascular imaging and why and how to implement this modality in your institution. The practical aspects and clinical value of myocardial blood flow quantification in PET in patients with cardiovascular disease. By Piotr Slomka, PhD, FACC, FASNC, Director of Innovation in Imaging and Professor of medicine and cardiology, Division of Artificial Intelligence in Medicine at Cedars-Sinai. One of the most important advances in nuclear cardiology is the opportunity to quantify myocardial blood flow (MBF) and myocardial flow reserve (MFR) routinely as part of myocardial perfusion imaging (MPI) with PET. Dr Slomka will review practical aspects of the MBF measurements with PET and discuss its clinical value in the management of cardiac patients. How to implement a cardiac PET myocardial perfusion imaging program ? ( Due to the institution policy, the recording could not be shared). By Sharmila Dorbala, MD, MPH, FASNC, Director of Nuclear Cardiology at Brigham and Women’s Hospital and Associate Professor of Radiology at Harvard Medical School. Dr. Dorbala will give an overview of the advantages of PET at identifying coronary artery disease (CAD), related workflow and current guidelines: She will also share her experience on how to implement a PET cardiac program.
Читать далее

Webinar Cardiac PET Imaging whats new and how to start

As our healthcare systems is constantly looking for more value medicine, the use of cardiac PET is rapidly expanding and becoming one of the pillar for cardiac imaging. Cardiac PET has been widely adopted because it provides : high diagnostic accuracy and it is safe, efficient and patient-centered. IBA invites you to attend a free webinar presented by 2 leading figures of Nuclear Medicine: Dr. Terrence Ruddy and Dr Parthiban Arumugam. What will you learn from the webinar ? Cardiac PET Myocardial Perfusion Imaging in 2020 Dr Ruddy will start with the basic of PET Cardiac imaging versus other modalities and share the recent advances in the field including the last results of the ISCHEMIA trial and coming CMS AUC (Appropriate User criteria) and its potential impact in the field. Dr. Terrence Ruddy, FRCPC,FACC is the Director of Nuclear Cardiology at University of Ottawa Heart Institute and a Professor of Medicine and Radiology at the University of Ottawa. How to implement a Cardiac PET Program in your site? Dr Arumugam will share his expertise on how to plan and implement a PET Cardiac Imaging Program covering resources (cost of equipment, tracers and staffing requirements) and supporting guidelines from national and international societies and also additional information that perfusion PET can offer over and above SPECT for a more precise diagnosis. Dr Parthiban Arumugam is a Consultant Nuclear Medicine Physician at Manchester University NHS Foundation Trust in the United Kingdom Society.
Читать далее

The Role of Specific PET PSMA imaging and SBRT in the Management of Prostate Cancer

In this webinar, the speakers will highlight the synergy between highly sensitive imaging, the definition of an intermediate stage between non-disseminated tumor and widespread metastatic disease (oligometastatic state) and high-precision radiation therapy (Stereotactic Body Radiation Therapy - SBRT) focused to treat the oligometastatic lesions. What will you learn from the webinar ? • Impact of PSMA PET on management of patients with oligo metastatic prostate cancer By Dr. Jeremie Calais, Director of the Clinical Research Program of the Nuclear Medicine and Theranostics Division at UCLA. Dr Calais will cover the concept of oligometastatic disease in prostate cancer patients and the impact of PSMA PET imaging on the therapy management of those patients. • The Role of SBRT in the treatment of oligometastatic prostate cancer: Why & how SBRT for these patients By PD Dr. med. Stefan Körber, First Senior Medical Doctor at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany Dr. Körber will describe how the oligometastatic status of prostate cancer patients is defined on the basis of PSMA PET/CT and which strategies and modalities are applied for SBRT treatment of these patients • Quality assurance for SBRT treatments By Dr. Kai Schubert, Medical Physicist at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany. The extremely high precision of SBRT requires an extensive program of Quality Assurance, both for the treatment machines as for the patient-specific treatment plans. Dr. Schubert will explain current strategies and future developments in this field.
Читать далее

Брошюры

Cyclone® KEY

EN CN

Synthera® +

EN RU CN

Cyclone® KIUBE

EN CN RU

Видео

IBA Synthera +

IBA Synthera +

Synthera®+ remains the most compact module on the market: up to 3 synthesizers can fit into a standard hot cell. Synthera®+ and Synthera®+ HPLC have both been fully redesigned to meet the most demanding production schedule of different radiotracers without opening the hot cell (less intervention, more safety). Synthera®+ can be equipped with the automatic IFP Loader (disposable production cassette dispenser) which can stack up to 4 cassettes. This allows it to perform consecutive runs of different compounds without opening the hot cell, resulting in nearly zero radiation exposure to the operator. This unique feature multiplies the capability of each module by a factor of four.

-

Synthera Extension

Synthera® Extension complements the functionality of the Synthera® family platform with its additional valves and a syringe driver for more complex processes such as postprocess purification in 68Ga liquid target productions* and elution of Ge/Ga generator when necessary.** [18F]NaF can also be produced on Synthera® Extension on routine basis. Additionally, diverse research applications have been developed on the Synthera® Extension as a standalone module, such as : (18F)NaF; separation/purification of 89Zr, 64Cu, 99mTc to obtain 89Zr-oxalate, 64Cu-chloride, 99mTc-pertechnetate, respectively. The module employs a re-usable support cassette where disposable tubing can be placed, which eliminates the need to use an additional IFP™ for complex syntheses.

*Patent pending on the complete liquid target process: EP15170854

***It depends on the type of generator.

Cyclone KIUBE custom Energy

Cyclone KIUBE Custom Energy

Dubai

Cyclone® KEY launch event : Dubai